Soltis Investment Advisors LLC Galectin Therapeutics Inc Transaction History
Soltis Investment Advisors LLC
- $1.23 Billion
- Q2 2025
A detailed history of Soltis Investment Advisors LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Soltis Investment Advisors LLC holds 140,750 shares of GALT stock, worth $644,635. This represents 0.02% of its overall portfolio holdings.
Number of Shares
140,750
Previous 140,750
-0.0%
Holding current value
$644,635
Previous $171,000
73.1%
% of portfolio
0.02%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding GALT
# of Institutions
95Shares Held
11.2MCall Options Held
134KPut Options Held
353K-
Vanguard Group Inc Valley Forge, PA2.18MShares$10 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$7.16 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.27MShares$5.8 Million0.01% of portfolio
-
Jane Street Group, LLC New York, NY749KShares$3.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$3.05 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $272M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...